What Igenomix does

Igenomix is a medical testing laboratory specializing in reproductive genetic services, founded in 2011 and headquartered in Paterna (Valencia), Spain, with US headquarters in Miami. The company operates as a wholly-owned subsidiary of Vitrolife Group following a 2021 acquisition by Swedish IVF device company Vitrolife. Igenomix offers a comprehensive portfolio of 11+ genetic tests across three reproductive phases: preconception (CGT carrier screening), preimplantation (PGT-A, PGT-A Plus, PGT-M, PGT-SR, EMBRACE, Family Balancing), and endometrial/prenatal assessment (ERA, EMMA, ALICE, EndomeTRIO, POC, SAT). The technology stack combines Next-Generation Sequencing (NGS), RT-PCR, and proprietary AI-powered bioinformatics algorithms trained on large clinical datasets including 200,000+ women's biopsies and 100,000+ embryo samples.

The company serves fertility clinics, IVF centers, reproductive health specialists, and patients undergoing fertility treatment globally, working directly with over 3,000 clinics across 20+ laboratories spanning North America, South America, Europe, Asia Pacific, and the Middle East. Tests are ordered by physicians and processed in CAP-accredited and CLIA-certified laboratories. Revenue is generated through laboratory genetic testing services billed via insurance reimbursement (Blue Cross Blue Shield, Kaiser Permanente, Progyny, among others) and direct patient payment, with patient financing available through third-party lenders. Igenomix maintains 600+ professionals globally and holds 4 patents including the foundational ERA patent (PCT/ES2009/000386), supported by over 500 peer-reviewed scientific publications providing clinical evidence for its tests.

The business model is B2B laboratory services with enterprise field sales targeting fertility clinics. Notable differentiators include the ERA test as the only endometrial receptivity test backed by an RCT, 98% accuracy claims for PGT-A and PGT-SR, and deep integration with Vitrolife Group's IVF device portfolio enabling end-to-end reproductive health workflow from culture media to genetic analysis. The company is recognized in major media (National Geographic, ABC News, BBC) and participates in leading scientific conferences (ASRM, ESHRE) to maintain clinical authority.

Name

Igenomix

Legal name

Igenomix USA, LLC

Website

https://igenomix.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Igenomix is a reproductive genetics laboratory offering 11+ genetic tests for fertility clinics and IVF patients globally. The company provides preconception, preimplantation, and prenatal testing using NGS and proprietary AI algorithms, serving 3,000+ clinics across 20+ laboratories worldwide as part of Vitrolife Group.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Reproductive genetic testing
• Preimplantation genetic testing
• Endometrial receptivity analysis
• IVF genetic diagnostics
• Carrier genetic screening

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Testing Services: Laboratory genetic testing services ordered by physicians for reproductive health patients. Revenue generated through insurance billing and direct patient payment. Services include ERA, EMMA, ALICE, PGT-A, PGT-M, PGT-SR, CGT, SAT, POC, and EMBRACE tests.
2. Insurance Reimbursement: Billing through accepted health insurance plans including Blue Cross Blue Shield, Kaiser Permanente, Progyny, and others. Some tests like EMMA & ALICE are not covered by insurance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Igenomix is a medical testing laboratory that provides specialized reproductive genetic testing services for fertility clinics, IVF centers, and patients undergoing assisted reproduction. Its portfolio covers preconception, preimplantation, and prenatal genetic tests—including ERA (endometrial receptivity), PGT-A/PGT-M/PGT-SR (preimplantation testing), EMMA/ALICE (endometrial microbiome), CGT (carrier screening), EMBRACE (non-invasive embryo testing), POC (miscarriage analysis), and SAT (sperm aneuploidy)—delivered through 20+ laboratories worldwide to 3,000+ fertility clinics.

Product overview

Igenomix is a medical testing laboratory specializing in reproductive genetic services that offers a comprehensive portfolio of genetic testing products organized across three reproductive phases: preconception, preimplantation, and prenatal. The core products include PGT-A and PGT-A Plus for embryo chromosomal screening, ERA for endometrial receptivity analysis, EndomeTRIO as an integrated endometrial health panel combining ERA/EMMA/ALICE, PGT-M for monogenic disorders, PGT-SR for structural rearrangements, CGT for carrier screening, and supporting tests including EMBRACE (non-invasive), POC, and SAT. The company operates as part of Vitrolife Group following acquisition in 2021, with 20+ laboratories worldwide and over 500 scientific publications supporting their product portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• Vitrolife Group: Combined global entity formed in 2021 when Vitrolife acquired Igenomix, creating a global leader in reproductive health combining reproductive genetic testing services with IVF device portfolio.

Products and services

• ERA (Endometrial Receptivity Analysis) A diagnostic test that evaluates endometrial receptivity using a 248-gene transcriptomic panel to determine each woman's unique personalized embryo transfer timing, synchronizing embryo transfer with the individualized window of implantation. Intended for fertility clinics and patients with recurrent implantation failure.
• EndomeTRIO A comprehensive endometrial health panel combining ERA, EMMA, and ALICE tests to provide a complete view of endometrial receptivity, microbiome balance, and detection of pathogenic bacteria causing chronic endometritis. For fertility clinics and patients.
• EMMA (Endometrial Microbiome Metagenomic Analysis) A screening test that evaluates the endometrial microbiome at the microbiological level using RT-PCR technology to identify bacteria at species level and assess microbial balance for embryo implantation suitability. For fertility clinics.
• ALICE (Analysis of Infectious Chronic Endometritis) A diagnostic test that detects pathogenic bacteria causing chronic endometritis using RT-PCR technology, identifying both culturable and non-culturable endometrial pathogens. For fertility clinics.
• CGT (Carrier Genetic Test) An advanced carrier genetic test using Next-Generation Sequencing (NGS) to determine whether couples are carriers of genetic mutations that could be transmitted to their children, examining over 500 genetic conditions including Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile-X Syndrome with 98% sensitivity. For preconception couples.
• PGT-A Plus An advanced 4-in-1 genetic test combining NGS with SNP analysis for aneuploidy screening, ploidy detection, DNA contamination detection, and cohort check without requiring parental samples. For fertility clinics performing IVF.
• PGT-A (Preimplantation Genetic Testing for Aneuploidies) A genetic test performed on embryos to identify numerical chromosomal abnormalities (aneuploidy) using Next-Generation Sequencing to analyze all 24 chromosomes, improving pregnancy rates by selecting chromosomally normal embryos. Achieves 98% accuracy via the Smart PGT-A bioinformatic algorithm.
• PGT-SR (Preimplantation Genetic Testing for Structural Rearrangements) A test for couples where one or both partners carry a known balanced structural chromosomal rearrangement, screening embryos for chromosomal imbalances resulting from parental structural rearrangements with 98% accuracy. For fertility clinics.
• PGT-M (Preimplantation Genetic Testing for Monogenic disorders) A custom-designed preimplantation genetic test for single gene disorders that significantly reduces the risk of having a child with an inherited genetic disorder, with capability for 300+ diseases and over 15,000 PGT-M cycles performed. For fertility clinics.
• Family Balancing Sex selection service using PGT-A technology alongside IVF to help patients select the desired sex of embryos while screening for chromosomal abnormalities. Handles 12,000 IVF cycles annually. For fertility clinics and patients.
• EMBRACE (Embryo Analysis of Culture Environment) A non-invasive test for prioritizing embryo transfer that analyzes cell-free DNA in spent blastocyst culture medium, avoiding invasive embryo biopsy while estimating chromosomal copy number. Achieves 78.2% concordance vs invasive biopsy. For fertility clinics.
• POC (Products of Conception) Analysis of fetal tissue from miscarriages using NGS technology to determine if pregnancy loss was due to chromosomal aneuploidy, providing results in 99% of cases. For clinics and patients following miscarriage.
• SAT (Sperm Aneuploidy Test) A diagnostic test analyzing sperm chromosomal abnormalities, evaluating aneuploidy and diploidy in chromosomes 13, 18, 21, X, and Y to study the genetic etiology of male infertility. For fertility clinics.
• PGT-A + ERA Synchrony A combined testing solution evaluating both the embryo (via PGT-A) and endometrial receptivity (via ERA) to maximize IVF success by transferring the right embryo at the right time. Analyzes 160,000 embryos per year. For fertility clinics.

Quantifiable outcome

• 3 in 10 women have displaced window of implantation requiring personalized transfer timing
• +11 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

One partnership is on record.

• Vitrolife GroupcoreStrategic or Co-development Partner · 1 January 2021In 2021, Vitrolife acquired Igenomix. Together they create Vitrolife Group, a global leader in reproductive health. The combination integrates Igenomix's portfolio of reproductive genetic testing services with Vitrolife's best-in-class IVF device portfolio to support clinics and patients across the entire fertility journey. Igenomix operates as a brand under Vitrolife Group with shared technologies and distribution channels.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera is the most direct competitor to Igenomix in reproductive genetic testing, offering Empower (carrier screening) and Spectrum PGT-A/PGT-M/PGT-SR, plus Signatera and other oncology tests. Both companies sell B2B to fertility clinics and compete head-to-head on PGT-A accuracy, turnaround, and clinic relationships.
• CooperSurgical (including Reprogenetics and PGT Sciences): CooperSurgical acquired Reprogenetics and PGT Sciences to compete directly in preimplantation genetic testing. It serves the same fertility clinic channel as Igenomix with PGT-A, PGT-M, and related services, alongside its broader IVF device/microtools portfolio.
• Genomic Prediction: Genomic Prediction is a direct PGT competitor that pioneered high-resolution PGT-A and polygenic embryo screening, appealing to elite IVF clinics and directly competing with Igenomix on accuracy, embryo-ranking algorithms, and scientific positioning.

Broad incumbents

• LabCorp (including Integrated Genetics / Esoterix): LabCorp offers broad reproductive and prenatal genetic testing through Integrated Genetics and esoteric lab services, competing with Igenomix on carrier screening, noninvasive prenatal testing, and molecular diagnostics while leveraging a much larger lab and payer footprint.
• Quest Diagnostics: Quest Diagnostics is a broad clinical laboratory incumbent with reproductive and genetic testing services (carrier screening, NIPT, prenatal diagnostics). It competes with Igenomix on payer relationships, scale, and routinized testing for the same patient populations.
• Myriad Genetics: Myriad Genetics is a broad genetic testing incumbent with a long-standing focus on hereditary cancer, but it also offers reproductive and carrier screening tests that compete with Igenomix's CGT, PGT-M, and other reproductive offerings.
• Invitae: Invitae (now a private company under its own structure) provides comprehensive genetic testing including reproductive health and carrier screening, positioning it as an overlapping competitor to Igenomix's CGT and broader genetics portfolio.

Emerging players

• GeneDx: GeneDx (a subsidiary of Sema4) provides rare disease and reproductive genetic testing with growing focus on carrier screening and prenatal diagnostics, competing with Igenomix in CGT and reproductive genomics channels.
• Progenity: Progenity develops reproductive and molecular diagnostics including prenatal testing, competing at the emerging/differentiation edge of the same reproductive health market as Igenomix despite its smaller commercial footprint.

Regional players

• BioReference Laboratories (OPKO Health): BioReference, an OPKO Health subsidiary, offers reproductive and clinical genetic testing with strong US regional presence, particularly in women's health and oncology, creating partial overlap with Igenomix's portfolio and patient channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/igenomix
• LinkedInlinkedin.com/company/igenomix

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Igenomix